CN Patent

CN120887884A — 用于癌症治疗的KRas抑制剂

Assigned to Taili Biotechnology Shanghai Co ltd · Expires 2025-11-04 · 1y expired

What this patent protects

本发明提供可用作KRas抑制剂的具有式(I)结构的化合物、包含这类化合物的药物组合物、制备这类化合物的方法以及这些化合物在治疗癌症中的用途。

USPTO Abstract

本发明提供可用作KRas抑制剂的具有式(I)结构的化合物、包含这类化合物的药物组合物、制备这类化合物的方法以及这些化合物在治疗癌症中的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN120887884A
Jurisdiction
CN
Classification
—
Expires
2025-11-04
Drug substance claim
No
Drug product claim
No
Assignee
Taili Biotechnology Shanghai Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.